Skip to main content

Table 2 Overall response rate and early tumor shrinkage 6 weeks after treatment

From: Tumour shrinkage at 6 weeks predicts favorable clinical outcomes in a phase III study of gemcitabine and oxaliplatin with or without erlotinib for advanced biliary tract cancer

  All (n = 103) GEMOX (n = 54) GEMOX plus erlotinib (n = 49) p-value
Early tumor shrinkage at 6 weeks     
  10 %≤ 53 (51.4 %) 22 40.7 %) 31 (63.2 %) 0.03
Response at 6 weeks (RECIST) 18 (17.4 %) 3 (5.6 %) 15 (30.6 %) 0.00
  Complete response 0 (0.0 %) 0 (0.0 %) 0 (0.0 %)  
  Partial response 18 (17.4 %) 3 (5.6 %) 15 (30.6 %)  
  Stable disease 72 (69.9 %) 44 (81.5 %) 28 (57.1)  
  Progressive disease 13 (12.6 %) 7 (13.0 %) 6 (12.2 %)  
Overall response (RECIST) 30 (29.0 %) 10 (18.6 %) 20 (40.8 %) 0.02
  Complete response 1 (0.9 %) 1 (1.9 %) 0 (0.0 %)  
  Partial response 29 (28.1 %) 9 (16.7 %) 20 (40.8 %)  
  Stable disease 50 (48.5 %) 32 (59.3 %) 18 (36.7 %)  
  Progressive disease 23 (22.3 %) 12 (22.2 %) 11 (22.4 %)